Phase II clinical and exploratory biomarker study of dacomitinib in recurrent and/or metastatic esophageal squamous cell carcinoma

The purpose of this study was to investigate the clinical activity, safety and predictive biomarkers of dacomitinib, an irreversible pan-HER inhibitor, in patients with recurrent or metastatic esophageal squamous cell carcinoma (R/M-ESCC). Patients, whose diseases were not amenable to curative treat...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Hyo Song, Kim, Sung-Moo, Kim, Hyunki, Pyo, Kyoung-Ho, Sun, Jong-Mu, Ahn, Myung-Ju, Park, Keunchil, Keam, Bhumsuk, Kwon, Nak-Jung, Yun, Hwan Jung, Kim, Hoon-Gu, Chung, Ik-Joo, Lee, Jong Seok, Lee, Kyung Hee, Kim, Dae Joon, Lee, Chang-Geol, Hur, Jin, Chung, Hyunsoo, Park, Jun Chul, Shin, Sung Kwan, Lee, Sang Kil, Kim, Hye Ryun, Moon, Yong Wha, Lee, Yong Chan, Kim, Joo Hang, Paik, Soonmyung, Cho, Byoung Chul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2015
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4792605/
https://www.ncbi.nlm.nih.gov/pubmed/26462025

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4792605/
https://www.ncbi.nlm.nih.gov/pubmed/26462025

Ejemplares similares